© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Elizabeth R. Plimack, MD, MS
Articles
Elizabeth Plimack, MD, MS, on Depth of Response in from the KEYNOTE-426 Trial
June 28, 2020
Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
June 09, 2020
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426.